Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Cowan M, et al. Among authors: nelson v. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. Gynecol Oncol. 2021. PMID: 34419285 Clinical Trial.
A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.
Dixit K, Singer L, Grimm SA, Lukas RV, Schwartz MA, Rademaker A, Zhang H, Kocherginsky M, Chernet S, Sharp L, Nelson V, Raizer JJ, Kumthekar P. Dixit K, et al. Among authors: nelson v. Cancers (Basel). 2024 Jun 4;16(11):2133. doi: 10.3390/cancers16112133. Cancers (Basel). 2024. PMID: 38893252 Free PMC article.
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W. Shah AN, et al. Among authors: nelson v. J Immunother Cancer. 2020 Feb;8(1):e000173. doi: 10.1136/jitc-2019-000173. J Immunother Cancer. 2020. PMID: 32060053 Free PMC article. Clinical Trial.
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. Karmali R, et al. Among authors: nelson v. Blood Adv. 2024 Apr 9;8(7):1612-1620. doi: 10.1182/bloodadvances.2023011369. Blood Adv. 2024. PMID: 38237077 Free PMC article. Clinical Trial.
Epidemiology of Anal Canal Cancer.
Nelson VM, Benson AB 3rd. Nelson VM, et al. Surg Oncol Clin N Am. 2017 Jan;26(1):9-15. doi: 10.1016/j.soc.2016.07.001. Surg Oncol Clin N Am. 2017. PMID: 27889039 Review.
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Karmali R, Abramson JS, Stephens DM, Barnes J, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Hochberg E, Takvorian T, Mi X, Nelson V, Gordon LI, Pro B. Karmali R, et al. Among authors: nelson v. Blood Adv. 2023 Dec 12;7(23):7361-7368. doi: 10.1182/bloodadvances.2023011271. Blood Adv. 2023. PMID: 37756532 Free PMC article.
342 results